Search
MEM 1003
go.drugbank.com/drugs/DB05547InvestigationalMEM 10003 was under investigation in clinical trial NCT00257673 (Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease) for the treatment of Alzheimer's Disease
Eldelumab
go.drugbank.com/drugs/DB06116InvestigationalMDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory
(+)-Mefloquine
go.drugbank.com/drugs/DB05636Investigational(+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to
Etoricoxib
go.drugbank.com/drugs/DB01628ApprovedInvestigationalWithdrawnIt is approved in more than 60 countries worldwide but not in the US. … Etoricoxib is a new COX-2 selective inhibitor.
Depatuxizumab mafodotin
go.drugbank.com/drugs/DB11731InvestigationalDepatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
BZL101
go.drugbank.com/drugs/DB05051InvestigationalBZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
Sampatrilat
go.drugbank.com/drugs/DB21283ExperimentalSampatrilat is a small molecule drug. Sampatrilat has a monoisotopic molecular weight of 584.25 Da.
Categories: Agents Acting on the Renin-Angiotensin SystemRibostamycin
go.drugbank.com/drugs/DB03615ApprovedWithdrawnRibostamycin is an aminoglycoside antibiotic[A187166] isolated from _Streptomyces ribosidificus_[A187178] listed as one of the World Health Organization's critically important antimicrobials.[L9071]